View in EDS HTML Full Text PDF Full Text

Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Saved in:
Bibliographic Details
Title: Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Authors: Marret G; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France., Isambert N; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France., Rezai K; Radio-Pharmacology Department, Institut Curie, Saint Cloud, France., Gal J; Epidemiology and Biostatistics Unit, Centre Antoine Lacassagne, Nice, France., Saada-Bouzid E; Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte D'Azur, Nice, France., Rolland F; Department of Medical Oncology, Institut René Gauducheau, Saint Herblain, France., Chausson M; UNICANCER, Paris, France., Borcoman E; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France., Alt M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France., Klijanienko J; Department of Pathology, Institut Curie, Paris, France., Vansteene D; Department of Medical Oncology, Institut René Gauducheau, Saint Herblain, France., Guigay J; Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte D'Azur, Nice, France., Kamal M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France., Bièche I; Department of Genetics, Institut Curie, Paris Descartes University, Paris, France.; INSERM U1016, Cochin Institute, Paris, France., Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France. christophe.letourneau@curie.fr.; INSERM U900, Institut Curie, Mines Paris Tech, Saint-Cloud, France. christophe.letourneau@curie.fr.; Paris-Saclay University, Paris, France. christophe.letourneau@curie.fr.
Corporate Authors: UNICANCER Head, Neck Group
Source: Investigational new drugs [Invest New Drugs] 2021 Dec; Vol. 39 (6), pp. 1641-1648. Date of Electronic Publication: 2021 Jul 28.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34322775
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Marret+G%22">Marret G</searchLink>; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France.<br /><searchLink fieldCode="AU" term="%22Isambert+N%22">Isambert N</searchLink>; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.<br /><searchLink fieldCode="AU" term="%22Rezai+K%22">Rezai K</searchLink>; Radio-Pharmacology Department, Institut Curie, Saint Cloud, France.<br /><searchLink fieldCode="AU" term="%22Gal+J%22">Gal J</searchLink>; Epidemiology and Biostatistics Unit, Centre Antoine Lacassagne, Nice, France.<br /><searchLink fieldCode="AU" term="%22Saada-Bouzid+E%22">Saada-Bouzid E</searchLink>; Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte D'Azur, Nice, France.<br /><searchLink fieldCode="AU" term="%22Rolland+F%22">Rolland F</searchLink>; Department of Medical Oncology, Institut René Gauducheau, Saint Herblain, France.<br /><searchLink fieldCode="AU" term="%22Chausson+M%22">Chausson M</searchLink>; UNICANCER, Paris, France.<br /><searchLink fieldCode="AU" term="%22Borcoman+E%22">Borcoman E</searchLink>; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France.<br /><searchLink fieldCode="AU" term="%22Alt+M%22">Alt M</searchLink>; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France.<br /><searchLink fieldCode="AU" term="%22Klijanienko+J%22">Klijanienko J</searchLink>; Department of Pathology, Institut Curie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Vansteene+D%22">Vansteene D</searchLink>; Department of Medical Oncology, Institut René Gauducheau, Saint Herblain, France.<br /><searchLink fieldCode="AU" term="%22Guigay+J%22">Guigay J</searchLink>; Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte D'Azur, Nice, France.<br /><searchLink fieldCode="AU" term="%22Kamal+M%22">Kamal M</searchLink>; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France.<br /><searchLink fieldCode="AU" term="%22Bièche+I%22">Bièche I</searchLink>; Department of Genetics, Institut Curie, Paris Descartes University, Paris, France.; INSERM U1016, Cochin Institute, Paris, France.<br /><searchLink fieldCode="AU" term="%22Le+Tourneau+C%22">Le Tourneau C</searchLink>; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France. christophe.letourneau@curie.fr.; INSERM U900, Institut Curie, Mines Paris Tech, Saint-Cloud, France. christophe.letourneau@curie.fr.; Paris-Saclay University, Paris, France. christophe.letourneau@curie.fr.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22UNICANCER+Head%2C+Neck+Group%22">UNICANCER Head, Neck Group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2021 Dec; Vol. 39 (6), pp. 1641-1648. <i>Date of Electronic Publication: </i>2021 Jul 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34322775
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10637-021-01152-z
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1641
    Titles:
      – TitleFull: Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Marret G
      – PersonEntity:
          Name:
            NameFull: Isambert N
      – PersonEntity:
          Name:
            NameFull: Rezai K
      – PersonEntity:
          Name:
            NameFull: Gal J
      – PersonEntity:
          Name:
            NameFull: Saada-Bouzid E
      – PersonEntity:
          Name:
            NameFull: Rolland F
      – PersonEntity:
          Name:
            NameFull: Chausson M
      – PersonEntity:
          Name:
            NameFull: Borcoman E
      – PersonEntity:
          Name:
            NameFull: Alt M
      – PersonEntity:
          Name:
            NameFull: Klijanienko J
      – PersonEntity:
          Name:
            NameFull: Vansteene D
      – PersonEntity:
          Name:
            NameFull: Guigay J
      – PersonEntity:
          Name:
            NameFull: Kamal M
      – PersonEntity:
          Name:
            NameFull: Bièche I
      – PersonEntity:
          Name:
            NameFull: Le Tourneau C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2021 Dec
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1573-0646
          Numbering:
            – Type: volume
              Value: 39
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Investigational new drugs
              Type: main
ResultId 1